Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative

Modern Pathology

Volumn 28, Issue 6, 2015, Pages 836-844

  Stelloo, Ellen ^a   Bosse, Tjalling ^a   Nout, Remi A ^a   Mackay, Helen J ^b   Church, David N ^c   Nijman, Hans W ^d   Leary, Alexandra ^e   Edmondson, Richard J ^f   Powell, Melanie E ^g   Crosbie, Emma J ^f   Kitchener, Henry C ^f   Mileshkin, Linda ^h   Pollock, Pamela M ⁱ   Smit, Vincent T ^a   Creutzberg, Carien L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g BARTS HEALTH NHS TRUST   (United Kingdom)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MISMATCH REPAIR PROTEIN PMS2; PROGESTERONE RECEPTOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CDKNA2 GENE; CLEAR CELL CARCINOMA; CTNNB1 GENE; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FBXW7 GENE; FEMALE; FGFR2 GENE; FGFR3 GENE; FOXL2 GENE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PIK3CA GENE; PPP2R1A GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PTEN GENE; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; TISSUE MICROARRAY; CLASSIFICATION; DNA MUTATIONAL ANALYSIS; ENDOMETRIUM TUMOR; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84930179410     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.43     Document Type: Article

References (37)

1. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37: 874-881
2. Scholten AN, Smit VT, Beerman H et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004;100:764-772
3. Han G, Sidhu D, Duggan MA et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013;26:1594-1604
4. Nedergaard L, Jacobsen M, Andersen JE. Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas. APMIS 1995;103: 511-518
5. Silverberg SG, Mutter GL, Kurman RJ et al. Tumors of the uterine corpus: epithelial tumors and related lesions In: Tavassoli FA, Stratton MR (eds) WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 221-232
6. Dedes KJ, Wetterskog D, Ashworth A et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8:261-271
7. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15:e268-e278
8. Le GM, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem 2014;60:98-110
9. Nout RA, Bosse T, Creutzberg CL et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation. Gynecol Oncol 2012;126:466-473
10. Church DN, Briggs SE, Palles C et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. HumMol Genet 2013;22:2820-2828
11. Church DN, Stelloo E, Nout RA et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107:402
12. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73
13. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18:5856-5864
14. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol 2009;5:27-32
15. Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health 2014;6:429-435
16. Jin Y, Li Y, Pan L. The target therapy of ovarian clear cell carcinoma. Onco Targets Ther 2014;7:1647-1652
17. Trialregister http://www.trialregister.nl/trialreg/admin/rctview-asp?TC= 729- 2014
18. van Oosterwijk JG, van Ruler MA, Briaire-de Bruijn IH et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer 2013;109:1214-1222
19. Stelloo E, Nout RA, Naves LC et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol 2014;133: 197-204
20. de Jong AE, van PM, Hendriks Y et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:972-980
21. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 2011;59:786-788
22. Garg K, Broaddus RR, Soslow RA et al. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012;31:48-56
23. Bosse T, Ter Haar NT, Seeber LM et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013;26:1525-1535
24. Guan B, Wang TL, Shih I. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71:6718-6727
25. van Eijk R, Stevens L, Morreau H et al. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. Exp Mol Pathol 2013;94:121-125
26. Spaans VM, Trietsch MD, Crobach S et al. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One 2014;9:e93451
27. van Roon EH, van PM, Middeldorp A et al. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?. BMC Cancer 2010;10:180
28. Mendivil A, Schuler KM, Gehrig PA. Nonendometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16:46-52
29. Meng B, Hoang LN, McIntyre JB et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 2014;134:15-19
30. Billingsley CC, Cohn DE, Mutch DG et al. Polymerase varepsilon (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. Cancer 2014;121:386-394
31. Zighelboim I, Goodfellow PJ, Gao F et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007;25: 2042-2048
32. Black D, Soslow RA, Levine DA et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24: 1745-1753
33. Arabi H, Guan H, Kumar S et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol 2009;113: 153-158
34. Mackay HJ, Gallinger S, Tsao MS et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46:1365-1373
35. Hoang LN, McConechy MK, Meng B et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 2014
36. Fadare O, Gwin K, Desouki MM et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol 2013;26:1101-1110
37. An HJ, Logani S, Isacson C et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004;17:530-537